Pathogen Panel Testing
Customize your policy alerts
Sign up for Blue Cross Blue Shield - Oklahoma Policy CPCPLAB045 alerts
Get alerted when Policy CPCPLAB045 changes without checking for updates manually.
Monitor payer policy activity
Defines outpatient laboratory reimbursement and coverage criteria for multiplex/molecular pathogen panel testing and describes tests that are not reimbursable under the Plan. Applies to providers submitting claims for outpatient pathogen panel tests for Blue Cross Blue Shield of Oklahoma members.
Added codes 87812, 0600U, 0610U.
Revised coverage statements to delineate respiratory multiplex PCR panel reimbursement by number of targets and patient immunocompromise status.
Added Note 1 defining signs and symptoms of respiratory tract infection.
Coverage Criteria
Reimbursable and Non-reimbursable Panel Testing
Covered when ALL of the following are met
Outpatient respiratory multiplex PCR panel (<=5 targets)
- Required clinical sign: At least one: temperature >=102°F, pronounced dyspnea, tachypnea, tachycardia.
These are explicit non-reimbursable categories.
Respiratory panel coverage
Coverage for multiplex respiratory panel testing is tiered based on patient symptoms and immune status.
Note 1 defines signs/symptoms; documentation required
Applies only to immunocompromised patients
Denial risk unless exception applies
This policy applies to outpatient testing only and defines reimbursement rules for multiplex, PCR-based pathogen panels. Multiplex PCR-based respiratory panels that test for up to 5 respiratory pathogens may be reimbursable when the patient is displaying signs and symptoms of a respiratory tract infection (see Note 1) and the clinical documentation includes at least one qualifying vital-sign criterion (for example, temperature ≥102° F, pronounced dyspnea, tachypnea, or tachycardia). Claims for panels that do not meet these outpatient clinical criteria may be denied.
The policy explicitly excludes several panel categories from reimbursement. Multiplex PCR-based panel testing of 6 or more respiratory pathogens is not reimbursable except where the specific symptomatic or immunocompromised exceptions apply as described in the policy update. In addition, panel testing performed on cerebrospinal fluid (CSF), molecular detection–based panels of pathogens in blood, molecular urine panels for UTI diagnosis, molecular wound infection panels, and molecular-based general microorganism screening panels are not reimbursable.
Policy revisions clarify that the guidance is focused on the outpatient setting and establish a tiered approach for respiratory multiplex PCR panels. For individuals displaying signs and symptoms of a respiratory tract infection (see Note 1), panels of up to 5 respiratory pathogens may be reimbursable. For immunocompromised individuals with respiratory symptoms, panels of up to 25 respiratory pathogens may be reimbursable as noted in the 04/24/2026 update.
The update history also added Note 1 to define qualifying signs and symptoms to support reimbursement under the symptomatic-individual rules and documents that the policy language was adjusted to emphasize outpatient-only applicability. Providers should ensure documentation of the required symptoms or immune status when submitting claims to align with the revised outpatient testing rules.
The following specimen types and specimen–indication combinations are listed as not reimbursable under this policy: panel testing of pathogens in cerebrospinal fluid (CSF); molecular detection–based panel testing of pathogens in blood; molecular detection–based urine pathogen panels for diagnosis of urinary tract infections (examples cited in history include GENETWORx Molecular PCR UTI Test); molecular-based panel testing to diagnose wound infections (example: GENETWORx PCR Wound Testing); and molecular-based panel testing for general microorganism screening (examples cited include MicroGenDX qPCR+NGS, SmartJane™, UroSwab®).
These categories are explicit exclusions and claims for these specimen types or general screening indications are not eligible for reimbursement under this outpatient policy.
Multiplex PCR-based respiratory panels that include 6 or more respiratory pathogen targets are generally not reimbursable. The policy makes an exception only when the test is ordered for an individual who is displaying signs and symptoms of a respiratory tract infection (Note 1) and meets the specific symptomatic or immunocompromised criteria: up to 5 targets for symptomatic individuals and up to 25 targets for symptomatic, immunocompromised individuals per the policy update.
For all other situations not described by those exceptions, claims for panels of ≥6 targets should be considered non‑reimbursable and are at risk for denial.
Covered Indications
Outpatient diagnosis of respiratory tract infection
Covered when ALL of the following are met
Order must be associated with outpatient setting and documentation of qualifying clinical signs/symptoms.
Panels of 6 or more respiratory pathogens are not reimbursable per policy.
Individuals displaying signs and symptoms of a respiratory tract infection (see Note 1)
Covered when ALL of the following are met
- Symptom requirement: At least one qualifying sign: temperature >=102°F, pronounced dyspnea, tachypnea, or tachycardia.
Denial risk unless exception applies
Coding
| No codes listed |
| 87812 | code added (description not provided in this excerpt) |
| 0600U | code added (description not provided in this excerpt) |
| 0610U | code added (description not provided in this excerpt) |
| 87428 | previously added code referenced in update history |
| 0556U | previously added code referenced in update history |
| 0563U | previously added code referenced in update history |
| 0564U | previously added code referenced in update history |
| 0240U | previously removed code referenced in update history |
| 0241U | previously removed code referenced in update history |
| 0370U | previously removed code referenced in update history |
Provider Actions and Billing Guidance
Prior Authorization / Clinical Requirement
Prior authorization or other clinical review may be required per plan benefit terms. Verify member coverage and any plan-specific prior authorization requirements before performing outpatient multiplex molecular testing. When prior authorization is required by the member's plan, submit clinical documentation that supports medical necessity per the reimbursement criteria (e.g., signs/symptoms per Note 1 or immunocompromised status when applicable).
- Check member benefit documents and prior authorization rules before ordering outpatient multiplex PCR or antigen panel testing.
- If PA is required by the specific plan, include clinical documentation demonstrating the individual meets the policy criteria (see Note 1 for required signs/symptoms).
- Authorization requirements may differ by plan and by place of service; this policy is specific to outpatient testing.
New Codes Added
New CPT and FDA EUA codes were added to this policy; ensure claims use the correct, up-to-date codes and check plan-specific PA rules for newly added codes.
Triggers for Denial
Claims for molecular or antigen panel testing that do not meet the outpatient symptomatic or immunocompromised criteria, or that include disallowed large panels or specimen types, are at risk for denial. Submit supporting documentation to avoid denials.
- Multiplex PCR-based panels of 6 or more respiratory pathogens are not reimbursable except as specified for symptomatic immunocompromised individuals per policy.
- Testing panels of 6+ pathogens in CSF, blood-based pathogen panels, urine pathogen panels for UTI diagnosis, wound infection panels, and general microorganism screening panels (e.g., qPCR+NGS) are not reimbursable.
- Claims for tests performed outside the outpatient setting may follow different rules; this policy applies to outpatient testing only.
Document Symptoms per Note 1
Document the presenting signs and symptoms for symptomatic testing. Note 1 defines qualifying signs and symptoms that must be present for outpatient multiplex respiratory testing reimbursement.
- Document at least one qualifying sign or symptom (Note 1) when billing for multiplex PCR-based respiratory panel testing: temperature ≥102° F, pronounced dyspnea, tachypnea, or tachycardia.
- For reimbursement of up to 5-respiratory-pathogen panels, patient must be displaying signs and symptoms of a respiratory tract infection as defined in Note 1.
- For expanded panels in immunocompromised patients (as described in policy history), document immunocompromised status and the qualifying signs/symptoms.
Documentation and Records
Providers must submit accurate and complete documentation upon request. Maintain clinical records supporting the medical necessity of tests billed and be prepared to provide additional documentation during claim review.
- Submit clinical notes, vital signs, and any lab or imaging results that support signs/symptoms and immunocompromised status where applicable.
- Claims are subject to coding edits and review; retain documentation and provide it when requested to support reimbursement.
Ordering Requirements
Ordering requirement: outpatient setting and documented qualifying signs/symptoms
Orders for respiratory multiplex PCR panels must be associated with the outpatient setting and include documentation of qualifying clinical signs/symptoms to support reimbursement.
- Document the outpatient site of service on the order and claim.
- Include at least one qualifying sign/symptom from Note 1 when claiming under symptomatic rules.
Ordering requirement: outpatient focus preserved after policy revisions
Policy revisions clarify that the guidance is focused on outpatient testing; while phrasing was adjusted in updates, the outpatient specificity remains and orders should reflect outpatient testing location and clinical justification.
- Previous language was revised to remove a leading phrase but retained the outpatient focus.
- Continue to document outpatient setting and clinical justification on orders and claims.
Not Covered
Not covered under this outpatient policy are multiplex PCR-based respiratory panels with 6 or more targets when they do not meet the symptomatic or immunocompromised exceptions. Also explicitly not covered are molecular panel testing performed on cerebrospinal fluid (CSF), molecular detection–based panel testing of pathogens in blood, and molecular urine panels for diagnosis of urinary tract infections.
Additionally, molecular-based panel testing intended for general microorganism screening (examples cited in the policy history include MicroGenDX qPCR+NGS, SmartJane™, and UroSwab®) and molecular wound infection panels are not reimbursable under this policy.
Molecular-based panel testing performed for broad or routine general screening of microorganisms is not reimbursable. The policy history lists exemplar tests to illustrate this category (for example, SmartJane™, UroSwab®, and MicroGenDX qPCR+NGS), and earlier revisions clarified these screening uses are excluded from reimbursement.
Multiplex panels that do not meet the coverage criteria—specifically multiplex respiratory panels of 6 or more targets outside the symptomatic or immunocompromised exceptions—are likewise considered not reimbursable and subject to denial.
Definitions
Background
Multiplex panels and other molecular assays detect multiple pathogens simultaneously and are used across specimen types including respiratory samples, cerebrospinal fluid, blood, urine, and wound specimens. The clinical utility varies by specimen type and patient presentation; some broad, multi‑target panels or screening uses do not improve clinical management and are therefore excluded from outpatient reimbursement under this policy.
This policy limits outpatient reimbursement primarily to respiratory multiplex PCR panels when clinical signs and symptoms are documented. It distinguishes specimen types and specific clinical indications to identify which molecular panel uses are appropriate for reimbursement and which are excluded.
Frequency Limits
Revision History
Policy update effective 04/24/2026 adding HCPCS/CPT/proprietary codes 87812, 0600U, and 0610U and implementing material changes to respiratory testing rules (tiered coverage by number of targets and immunocompromise status).
01/07/2026 entry listed in Policy Update History referencing the 04/24/2026 summary of changes (codes added and respiratory panel revisions).
09/26/2025 update revised respiratory coverage language to: reimbursable up to 5 targets for symptomatic individuals, up to 25 targets for symptomatic immunocompromised individuals, and non-reimbursable for 6+ targets in other situations; added Note 1 defining signs and symptoms and added/removed multiple codes (87428, 0556U, 0563U, 0564U added; 0240U, 0241U, 0370U, 0373U, 0374U removed).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.